In animal model experiments conducted on 30 male rabbits with dyslipidemia, treated with 10-Dehydrogingerdione, a novel cholesteryl ester transfer protein (CETP) inhibitor, which is able to suppress PCSK9 expression, induced a marked decrease in the soluble sCD40L and sP-selectin [62]. The gene discussed is PCSK9; the disease is metabolic syndrome.